Idogen is a company that is developing tolerogenic cell therapies with the aim to treat conditions or diseases caused by an unwanted immune response in the patient. As the company now approaches clinical phase with its most advanced development program IDO 8, Redeye is intensifying their coverage of Idogen and have today published an updated analysis of Idogen.
In summary, Redeye’s report describes Idogen as a company developing novel treatments where there are large unmedical needs. In the most advanced program, IDO 8, the company has developed a cell therapy for patients with Hemophilia A, who have developed antibodies, a k a ”inhibitors”. Against their vital factor VIII treatment. The first clinical study within this program has, as previously communicated, obtained regulatory approval in both Sweden and Norway. The first patient is planned to be included in this phase 1/2a study during autumn.
”Redeye has covered us for a long time and is now making an extensive update as we approach clinical phase” says Christina Herder, acting CEO. ”At the same time, we are also intensifying our efforts to reach potential external partners for continued development and commercialization”.
Disclaimer: HC Andersen Capital receives payment from Idogen for a DigitalIR/Corporate Visibility agreement.